Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The Cochrane reviews are widely considered to be among the most rigorous, systematic, and objective reviews of data related to specific medical topics. An initial Cochrane review of data on screening for prostate cancer was carried out in 2006, and it was updated in June 2009.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, mortality, PSA, risk, screeing, testing | 2 Comments »
The roles and behaviors of primary care physicians (PCPs) in the US in encouraging men to or discouraging men from having a PSA test to assess possible risk for prostate cancer are still not well understood.
Filed under: Diagnosis, Risk | Tagged: PCP, primary care, PSA, screening, testing | 6 Comments »
The expected promotion of the Beckman Coulter Pro-PSA test as being better and more accurate than standard PSA testing is apparently about to begin. The first round appears to have come with a media release yesterday from Northwestern University.
Filed under: Diagnosis, Risk | Tagged: biopsy, pro-PSA, [-2]pro-PSA | 3 Comments »
One of the great prostate cancer successes in recent years has been the development of the Prostate Cancer Clinical Trials Consortium (PCCTC), which is primarily focused on the conduct of early stage (Phase I and Phase II) trials of promising new drugs for the treatment of prostate cancer.
Filed under: Drugs in development | Tagged: Cancer Immunology Trials Network, CITN, PCCTC, Prostate Cancer Clinical Trials Consortium | Leave a Comment »
It will come as little surprise to regular readers of this blog that androgen deprivation therapy (ADT) is associated with effects on health-related quality of life. However, few studies have attempted to assess the impact of ADT on true “physical well-being.”
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, physical well-being, quality of life | 3 Comments »
According to a report issued earlier today by PhRMA (formerly known as the Pharmaceutical Research and Manufacturers Association), there are approximately 80 drugs currently in clinical development for the treatment of prostate cancer.
Filed under: Drugs in development | 4 Comments »
To date there has only been one test available for assay of levels of circulating tumor cells (CTCs) in men with prostate cancer: the CellSearch test made by Veridex. This test is widely recognized to come with a variety of challenges, and the potential of CTCs in assessing risk for progression of prostate cancer (and [...]
Filed under: Living with Prostate Cancer, Management | Tagged: circulating tumor cells, circulating tumor stem cells, CTC, CTSC, outcome, prognosis | Leave a Comment »
An article in the new journal Cancer Discovery has suggested that the drug digoxin (originally derived from foxgloves, and also known as digitalis) may have utility in the management of prostate cancer.
Filed under: Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: digoxin | Leave a Comment »
The ability to identify men at high risk for — and subsequently with — more aggressive forms of prostate cancer relatively early in their lives is obviously an important goal. Younger men tend to recover better from initial treatment for localized prostate cancer than their older peers.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: age, military, outcome, young | Leave a Comment »
Dr. William Catalona has long been one of the strongest advocates of prostate cancer screening. He has been a key individual in the development and promotion of PSA testing for some 20 years, and he believes passionately that prostate cancer screening saves lives. We respect his beliefs and his right to express those beliefs.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: data, manipulation, mortality | 15 Comments »
A report in New Zealand’s Old Dominion Post would appear to typify a classic type of sad over-reaction to the results of the recent Norrkoping screening study (on which we commented last week).
Filed under: Diagnosis, Risk | Tagged: New Zealand, PSA, screening, testing | 4 Comments »
Lapatinib — which is already approved for the treatment of selected patients with advanced breast cancer — is an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases, both of which may be relevant to activation of the androgen receptor and therefore may be involved in the progression of advanced forms of [...]
Filed under: Drugs in development, Management, Treatment | Leave a Comment »
There has been a lot of media “chatter” over the past 3 days about an article published in the journal Cancer Research. The article suggests that an investigational genetic test can project the presence of prostate cancer in biopsy-based specimens with an average accuracy of 97 percent.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, gene, genetics, profiling, risk | Leave a Comment »
The Cancer Prevention and Treatment Institute of Texas (CPRIT), which we first wrote about back in late 2008, has recently made a major new grant award for prostate cancer research. With an endowment of $3 billion, CPRIT is one of the largest cancer research funding organizations in the US today.
Filed under: Drugs in development, Prevention | Tagged: Cancer Prevention and Research Institute of Texas, CPRIT, research, Texas | Leave a Comment »
A new report just published as an open access, full-text article at BMJ.com is going to further confuse the issue of whether mass, population-based screening for prostate cancer is or isn’t a good idea.
Filed under: Diagnosis, Risk, Uncategorized | Tagged: DRE, mortality, Norrkoping, outcome, PSA, screening, Sweden | 14 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site